SCYX
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Larry Hoffman is recorded as CFO at Scynexis Inc (SCYX). The newest filing on record that lists Larry Hoffman as CFO at Scynexis Inc (SCYX) is dated May 12, 2022. Larry Hoffman has spoken on 2 earnings calls across 1 company, most recently for Scynexis Inc on August 15, 2022. Scynexis Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Scynexis Inc includes David Angulo (CEO and Board Member), David Angulo, M.D. (CEO and Board Member), Dr. David Angulo (CEO and Board Member) and 7 others.
“BREXAFEMME increased its net product revenues from $700,000 in the first quarter of 2022 to $1.3 million in the second quarter of 2022. R&D expense for the second quarter of 2022 increased to $7.1 million from $4.7 million for the second quarter of 2021.”
“For the fourth quarter of 2021, BREXAFEMME generated $600,000 in net revenues, the first full quarter of sales for BREXAFEMME since its approval by the FDA in June 2021.”
Start not stated–present
Last confirmed May 12, 2022
SCYX
Drug Manufacturers - Specialty & Generic · Healthcare
CFO